Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Combination With DMARDs in Active Rheumatoid Arthritis
NCT00117091Phase 3Completed
- Sponsor
- Amgen
- Modality
- Cytokines & Interferons
01
Overview
Phase 3, open-label, single-arm trial of anakinra in rheumatoid arthritis (RA), sponsored by Amgen. Primary endpoint: Percentage of subjects continuing Kineret® therapy at 48 weeks. Status: completed.
02
Drugs
anakinra
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00117091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117091.